Investigational Cell Therapy Bemdaneprocel Shows Sustained Safety and Promising Motor Improvements at 36 Months in Parkinson’s Disease Trial
Bayer AG and its subsidiary BlueRock Therapeutics LP have announced encouraging 36-month follow-up data from the Phase I exPDite clinical trial of bemdaneprocel (BRT-DA01), an investigational cell therapy aimed at…